Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: JCSM Clin Rep. 2021 Sep 5;6(4):128–136. doi: 10.1002/crt2.42

Table 3.

Log-Rank Analysis for Overall Survival

Group Median survival time (95% CI) (Months) P value Survival comparison group P value
All patients (n=126) 19.5 (14.7, 26.5) Cachexia, SUVMax ≥8.5 vs
no cachexia, SUVMax ≥8.5		 .7832
Cachexia* SUV Max .0007
 Cachexia, SUVMax≥8.5 (n=47) 12.4 (8.2, 23.2) Cachexia, SUVMax ≥8.5 vs
cachexia, SUVMax <8.5		 .8313
 No cachexia, SUVMax≥8.5 (n=25) 14.2 (10.6, 20.4)
 Cachexia, SUVMax <8.5 (n=21) 16.0 (12.4, 26.5) Cachexia, SUVMax ≥8.5 vs
no cachexia, SUVMax <8.5		 .0003
 No cachexia, SUVMax <8.5 (n=33) Did not reach median
Primary tumor SUV Max .0016 No cachexia, SUVMax ≥8.5 vs
cachexia, SUVMax <8.5		 .7345
 <8.5 (n=54) 26.7 (20.1, .)
 ≥8.5 (n=72) 13.8 (10.6, 18.8) No Cachexia, SUVMax ≥8.5 vs
no cachexia, SUVMax <8.5		 <.0001
Cachexia at diagnosis .0119
 No cachexia (n=58) 32.8 (19.5, .) Cachexia, SUVMax <8.5 vs
no cachexia, SUVMax <8.5		 .0007
 Cachexia (n=68) 14.7 (11.3, 19.2)